Regulus Therapeutics has entered into collaboration with researchers at the University of California San Diego’s school of medicine to develop novel treatments for angiogenic diseases using microRNA therapeutics.
The research will combine Regulus’ microRNA platform with the US university’s expertise in animal models of angiogenesis to discover anti-angiogenic microRNA-targeted therapies that could be used for treatment of human disease.
The collaborative research programme was the recent recipient of a University of California Discovery Grant that promotes collaborations between the its researchers and industry partners.
Angiogenesis, which is the formation of new blood vessels, is an important event that contributes to the severity of cancer, diabetes, macular degeneration, inflammatory disease and arthritis.
MicroRNAs have been implicated in regulating biological networks involved in angiogenesis.
